Research peptides are not approved for human use in most countries including India. This page is for educational purposes only. Consult a physician before use.
What is PT-141?
PT-141 (bremelanotide) is a cyclic heptapeptide and melanocortin receptor agonist. It is a synthetic analogue of Melanotan II, which was originally developed as a tanning peptide (it activates MC1R to increase melanin production). During Melanotan II trials, researchers observed unexpected and significant sexual arousal effects, leading to the development of PT-141 as a dedicated sexual health compound with the tanning side effect minimized.
Bremelanotide was approved by the FDA in June 2019 as Vyleesi (Palatin Technologies/AMAG Pharmaceuticals) for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women — making it the first drug approved for this indication that works through a central nervous system mechanism rather than a hormonal or vascular approach.
Mechanism: Central vs Peripheral Action
Understanding PT-141 requires understanding why it differs fundamentally from PDE5 inhibitors:
PDE5 inhibitors (sildenafil/Viagra, tadalafil/Cialis): Work peripherally — they inhibit the enzyme that breaks down cGMP in vascular smooth muscle, causing vasodilation in genital tissue and facilitating erection. They do not affect sexual desire, arousal motivation, or the cognitive/emotional aspects of sexual response. They work on the plumbing, not the desire.
PT-141 / Bremelanotide: Works centrally via melanocortin receptors (primarily MC4R) in the hypothalamus. MC4R activation triggers dopaminergic signaling pathways in the mesolimbic system — the same reward pathways involved in motivation and pleasure. This increases sexual desire and arousal motivation from the CNS, affecting the psychological experience of sexual interest rather than just the mechanical response.
The implications are significant: PT-141 can be effective in cases where PDE5 inhibitors fail — particularly psychogenic erectile dysfunction where the issue is desire/arousal rather than vascular insufficiency, and in women where PDE5 inhibitors have minimal effect.
FDA Approval Context
The FDA approval of Vyleesi (bremelanotide) in 2019 followed two Phase III clinical trials (RECONNECT trials) enrolling 1,247 premenopausal women with HSDD. Key findings:
- Statistically significant improvement in the number of satisfying sexual events per month
- Significant reduction in distress associated with low sexual desire
- Primary side effects: nausea (40%), flushing (20%), headache (11%), transient blood pressure increase
- Nausea was dose-dependent and the primary reason for discontinuation
The FDA approved it with a Risk Evaluation and Mitigation Strategy (REMS) due to the blood pressure effect — it is contraindicated in those with cardiovascular disease and those taking nitrates.
The male use case is off-label — PT-141 is used by physicians for men with psychogenic erectile dysfunction, desire-related ED, or ED that doesn't respond to PDE5 inhibitors, but formal FDA approval for men does not exist.
PT-141 vs PDE5 Inhibitors Comparison
| Property | PT-141 (Bremelanotide) | Sildenafil (Viagra) | Tadalafil (Cialis) |
|---|---|---|---|
| Mechanism | Central — MC4R agonist, dopaminergic | Peripheral — PDE5 inhibitor, vasodilator | Peripheral — PDE5 inhibitor, vasodilator |
| Primary effect | Increases sexual desire and arousal | Facilitates erection mechanics | Facilitates erection mechanics |
| Administration | Subcutaneous injection | Oral tablet | Oral tablet (daily or as-needed) |
| Onset | 45-90 minutes | 30-60 minutes (with sexual stimulation) | 30-120 minutes (up to 36 hr window) |
| Effective without stimulation? | Yes — increases desire centrally | Requires sexual stimulation | Requires sexual stimulation |
| FDA approval | Approved for women (HSDD); off-label for men | Approved for erectile dysfunction | Approved for ED and BPH |
| Main side effect | Nausea, transient BP increase | Headache, flushing, visual changes | Back pain, muscle aches, headache |
| Complementary use | PT-141 + tadalafil combination is used for men with both desire and mechanical ED components | ||
PT-141 causes a transient increase in blood pressure (approximately 6-10 mmHg systolic) lasting 4-12 hours after injection. It is contraindicated with nitrates (including recreational nitrites) due to risk of severe hypotension. It is also contraindicated in uncontrolled hypertension and high-risk cardiovascular disease. Physician assessment of cardiovascular risk is mandatory before use.
Dosing Protocol
FDA-approved female dosing (Vyleesi): 1.75mg subcutaneous injection, 45 minutes before anticipated sexual activity. Maximum once per 24 hours, 8 times per month.
Off-label male dosing (physician-supervised): 0.5-2mg subcutaneous injection, 45-90 minutes before activity. Starting at 0.5mg to assess nausea tolerance. Many men find 1-1.5mg optimal for effect vs side effect balance. Frequency limitations same as FDA labeling.
Anti-nausea premedication (e.g., ondansetron) 30 minutes before PT-141 injection significantly reduces nausea incidence and is commonly used in clinical practice.
Frequently Asked Questions
PDE5 inhibitors work peripherally on blood vessels — they improve erection mechanics by increasing blood flow to genital tissue. PT-141 works centrally in the brain via melanocortin-4 receptors, triggering dopaminergic pathways that increase sexual desire and arousal motivation. PT-141 affects the desire/motivation component; PDE5 inhibitors affect the mechanical response. They are complementary rather than competing mechanisms.
PT-141 (Vyleesi) is FDA-approved in the US for women with HSDD. It is not approved by India's CDSCO. It is available as a research peptide through unregulated channels in India. Physician supervision is strongly recommended due to the blood pressure effects and cardiovascular contraindications that require clinical assessment before use.
Off-label male dosing ranges from 0.5-2mg subcutaneous injection, 45-90 minutes before activity. Start at the lowest effective dose (0.5-1mg) to gauge nausea response. Taking anti-nausea medication (ondansetron 4mg) 30 minutes prior significantly reduces side effects. PT-141 is not FDA-approved for men, so dosing is based on physician judgment and pharmacological extrapolation from the female approval data.
Nausea is the most common (40% at the 1.75mg FDA dose) — dose-dependent and manageable with anti-emetics. Transient blood pressure increase (6-10 mmHg) lasting 4-12 hours. Flushing, headache, injection site reaction, and hyperpigmentation with repeated use at high doses (Melanotan II tanning mechanism is partially retained). The cardiovascular effects require physician screening before use.